Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 4/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 15/20 | 0.51 |
| ▸ | MAP3K7 | O43318 | 7/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351228 | 0.94 | IRAK4 (0.49) | INSRALKIRAK4MAP3K7CYP3A4 | |
| SCHEMBL1305751 | 0.88 | JAK2 (0.44) | INSRALKIRAK4MAP3K7KDR | |
| SCHEMBL352484 | 0.83 | IRAK4 (0.51) | INSRALKIRAK4MAP3K7KDR | |
| SCHEMBL1306082 | 0.83 | IRAK4 (0.45) | IRAK4MAP3K7KDRAURKB | |
| SCHEMBL1305758 | 0.82 | SYK (0.42) | IRAK4MAP3K7KDRAURKB | |
| SCHEMBL350782 | 0.82 | IRAK4 (0.46) | IRAK4MAP3K7KDRAURKB | |
| SCHEMBL352257 | 0.82 | IRAK4 (0.46) | INSRALKIRAK4MAP3K7KDR | |
| SCHEMBL350151 | 0.81 | IRAK4 (0.52) | IRAK4MAP3K7AURKB | |
| SCHEMBL1306157 | 0.81 | INSR (0.51) | INSRALKIRAK4MAP3K7CYP3A4 | |
| SCHEMBL352279 | 0.80 | IRAK4 (0.44) | IRAK4MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960372-B1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | claimed |
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | claimed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | claimed |
| EP-1960372-A1 | KINASE INHIBITORS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| WO-2007070872-A1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | MIDCAP FINANCIAL TRUST | 2016-01-28 | — | — | US | disclosed |
| US-9096542-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | INSR 996/4885ALK 230/4885IRAK4 239/4885 |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | INSR 996/4885ALK 230/4885IRAK4 239/4885 |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, JAK2 | INSR 888/4885ALK 221/4885IRAK4 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.